ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show - FiercePharma
- ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show FiercePharma
- Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020 Business Wire
- View Full Coverage on Google News